All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

CheckMate-9ER Post-Hoc Analysis Seeks to Identify Efficacy Biomarkers for Nivolumab/Cabozantinib in RCC

September 19th 2024

Elevated fucosylation and sialylation of serum proteins were negative prognostic factors in RCC after treatment with nivolumab plus cabozantinib or sunitinib.

Elacestrant Plus Abemaciclib Demonstrates Clinical Benefit in Pretreated ER+/HER2– Metastatic Breast Cancer

September 18th 2024

Elacestrant plus abemaciclib demonstrated clinical activity and manageable safety in pretreated ER+/HER2– metastatic breast cancer.

Rare Case Study of ALK+ Advanced RCC Highlights Drive for Personalized Medicine in Kidney Cancer

September 18th 2024

Alexandra Drakaki, MD, dives into a case study of a patient with ALK-positive RCC that exemplified the importance of NGS and precision medicine in kidney cancer.

Experts Highlight Top Findings From the 2024 IASLC World Conference on Lung Cancer

September 18th 2024

Experts across the lung cancer treatment space impart their key takeaways from research shared at the 2024 IASLC World Conference on Lung Cancer.

Understanding CAR T-Cell Therapy for Cancer: Mayo Clinic Expert Explains How It Works

September 18th 2024

Richard Vile, PhD, explains how CAR-T cell therapy works, including the benefits, risks and realities of treatment.

FDA Grants Orphan Drug Designation to CF33-hNIS for Cholangiocarcinoma

September 18th 2024

The FDA has granted orphan drug designation to the novel oncolytic virotherapy CF33-hNIS for cholangiocarcinoma.

FDA Grants Fast Track Designation to ICT01 Plus Azacitidine/Venetoclax in Treatment-Naive AML

September 18th 2024

ICT01 plus azacitidine and venetoclax has received fast track designation from the FDA in patients with untreated AML unfit for induction chemotherapy.

Lenvatinib Plus Pembrolizumab Affords Deep and Durable Responses in Endometrial Cancer

September 18th 2024

Lenvatinib plus pembrolizumab led to tumor responses regardless of mismatch repair–proficient status, histology, and prior adjuvant therapy.

Dato-DXd Demonstrates Efficacy, Safety in Platinum-Resistant Ovarian and Endometrial Cancers

September 18th 2024

Datopotamab deruxtecan shows antitumor activity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy.

Approval Sought for Belantamab Mafodotin Combos for R/R Multiple Myeloma in Japan

September 18th 2024

Japan’s Ministry of Health, Labour, and Welfare has accepted the NDA for belantamab mafodotin plus bortezomib/dexamethasone in relapsed/refractory myeloma.

NCCN Guideline Updates Expand IO/TKI Options and Precision Medicine Approaches in RCC

September 18th 2024

Moshe Ornstein, MD, MA, discusses the implications of updates to NCCN guidelines for the management of non–clear cell and clear cell renal cell carcinoma

FDA Approves Pembrolizumab Plus Chemo for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

September 17th 2024

The FDA has approved frontline pembrolizumab plus chemotherapy for use in unresectable advanced or metastatic malignant pleural mesothelioma.

Ipilimumab Plus Nivolumab Increases 12-Month OS Rate vs SOC in nccRCC

September 17th 2024

Ipilimumab given in combination with nivolumab met the primary end point of 12-month OS rate vs SOC in patients with nccRCC in the SUNNIFORECAST trial.

Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC

September 17th 2024

Benmelstobart plus anlotinib improved PFS, OS, and ORR vs sunitinib in first-line advanced renal cell carcinoma.

FDA Approves Adjuvant Ribociclib in HR+/HER2– Breast Cancer

September 17th 2024

The FDA approved adjuvant ribociclib plus an aromatase inhibitor in patients with HR-positive, HER2-negative early breast cancer.

FDA Grants RMAT Designation to P-BCMA-ALL01 for R/R Multiple Myeloma

September 17th 2024

The FDA has granted regenerative medicine advanced therapy designation to P-BCMA-ALL01 for relapsed/refractory multiple myeloma.

Patritumab Deruxtecan Meets PFS End Point in Pretreated EGFR-Mutant NSCLC

September 17th 2024

The HERTHENA-Lung02 trial met its primary end point of improved PFS with patritumab deruxtecan in pretreated EGFR-mutated non–small cell lung cancer.

Tislelizumab Receives Israeli Approval in Unresectable or Metastatic ESCC

September 17th 2024

Tislelizumab has been approved by the Israeli Ministry of Health for pretreated patients with unresectable or metastatic esophageal squamous cell carcinoma.

Fox Chase Cancer Center to Host Symposium Celebrating 20-Year Anniversary of Nobel Prize for Discovery That Advanced Understanding of Cancer and Development of New Drugs

September 17th 2024

Fox Chase Cancer Center’s Center for Immunology will host its 14th Annual Scientific Symposium on Friday, October 18, 2024.

Updated NCCN Kidney Cancer Guidelines Bring New Recommendations for Advanced Non–Clear Cell RCC

September 17th 2024

Bradley McGregor, MD, shared his insights on the updated NCCN Clinical Practice Guidelines in kidney cancer.